Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Tuberous Sclerosis 2Neoplasms 2Sturge-Weber Syndrome 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Gastroenteropancreatic Neuroendocrine Tumors 1Epilepsy 1Cognitive Dysfunction 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 16Fluorouracil 6Irinotecan 4Cisplatin 4Capecitabine 4Oxaliplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3nimotuzumab 2Taxes 2Phytotherapy 2Leucovorin 2Drug Therapy 2surufatinib 1rubitecan 1racemetyrosine 1pertuzumab 1pembrolizumab 1methylnaltrexone 1folfirinox 1cyclopropapyrroloindole 1camrelizumab 1Trastuzumab 1Tranexamic Acid 1Standard of Care 1Sirolimus 1Radiotherapy 1Positron Emission Tomography Computed Tomography 1Phenytoin 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Pancreatic Neoplasms × Sirolimus × Clear all
NCT03512756 2024-11-06

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

Tyme, Inc

Phase 2/3 Terminated
130 enrolled 13 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡